Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Am J Transplant ; 10(3): 602-11, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20055799

RESUMEN

The first liver transplantation (LTx) in Sweden was performed in 1984, but brain death as a legal death criterion was not accepted until 1988. Between November 1984 and May 1988, we performed 40 consecutive LTxs in 32 patients. Twenty-four grafts were from donors after cardiac death (DCD) and 16 grafts from heart-beating donors (HBD). Significantly, more hepatic artery thrombosis and biliary complications occurred in the DCD group (p < 0.01 and p < 0.05, respectively). Graft and patient survival did not differ between the groups. In the total group, there was a significant difference in graft survival between first-time LTx grafts and grafts used for retransplantation. There was better graft survival in nonmalignant than malignant patients, although this did not reach statistical significance. Multivariate analysis revealed cold ischemia time and post-LTx peak ALT to be independent predictive factors for graft survival in the DCD group. In the 11 livers surviving 20 years or more, follow-up biopsies were performed 18-20 years post-LTx (n = 10) and 6 years post-LTx (n = 1). Signs of chronic rejection were seen in three cases, with no difference between DCD and HBD. Our analysis with a 20-year follow-up suggests that controlled DCD liver grafts might be a feasible option to increase the donor pool.


Asunto(s)
Muerte , Trasplante de Hígado/métodos , Donantes de Tejidos , Adulto , Femenino , Estudios de Seguimiento , Supervivencia de Injerto , Arteria Hepática/patología , Humanos , Lactante , Masculino , Persona de Mediana Edad , Análisis Multivariante , Trombosis/patología , Resultado del Tratamiento
2.
Eur J Surg Oncol ; 43(4): 751-757, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28109674

RESUMEN

INTRODUCTION: A single-center nonrandomized clinical trial was performed to assess the safety and efficacy of IRE ablation of liver tumors in humans. METHODS: 38 malignant liver tumors on 30 patients were treated with IRE between September 2011 and September 2014. Treatment was with curative intent, and the diagnoses were colorectal cancer with liver metastases (CRLM) (n = 23), hepatocellular carcinoma (HCC) (n = 8) and other metastasis (n = 7). Patients were selected when surgery, radiofrequency ablation (RFA) or microwave ablation (MWA) was not an option, and when they met inclusion criteria (tumor size < 3 cm, 1-2 tumors). Patients were followed-up at 1 and 6 months with a contrast-enhanced computed tomography (CE-CT), and contrast-enhanced ultrasound (CE-US) at 3 months. RESULTS: Ablation success was defined as no evidence of residual tumor in the ablated area as confirmed by CE-CT and CE-US. At 3 months ablation success was 78.9%, and 65.8% at 6 months. There was no statistically significant difference between tumor volume (<5 cm3 vs >5 cm3, p = 0.518), and between diagnosis (CRLM vs HCC, p = 0.084) in terms of local recurrence. Complications were classified according to the standardized grading system of Society of Interventional Radiology (SIR). A minor complication occurred in six patients (20%), one patient (3.3%) suffered from a major complication (bile duct dilatation and stricture of the portal vein and bile duct). No mortalities occurred at 30 days. CONCLUSIONS: IRE appears to be a safe treatment modality for a selected group of patients with liver tumors and offers high local tumor control at 3 and 6 months.


Asunto(s)
Técnicas de Ablación/métodos , Carcinoma Hepatocelular/terapia , Electroporación/métodos , Neoplasias Hepáticas/terapia , Complicaciones Posoperatorias/epidemiología , Adulto , Anciano , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Carcinoma Hepatocelular/diagnóstico por imagen , Neoplasias Colorrectales/patología , Femenino , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/sangre , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Ultrasonografía
3.
Transplantation ; 63(1): 74-80, 1997 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-9000664

RESUMEN

Cyclosporine (CsA) and tacrolimus (FK506) have recently been reported to inhibit canalicular transport of bile acids in vitro and thereby possibly induce cholestasis. A relative reduction of chenodeoxycholic acid (CDCA) has been observed after liver transplantation when CsA is used as immunosuppressant. We tested the hypothesis that CsA induces cholestasis and reduces CDCA secretion as compared with treatment with monoclonal antibodies (OKT3), and that CsA differs from FK506 with regard to its effects on biliary lipid secretion. Bile flow, biliary lipid secretion rates, and biliary bile acid composition were determined during the first 10 days after transplantation in 29 liver transplant recipients. Two prospective randomized studies were performed that compared CsA and OKT3 and compared CsA- and FK506-based regimens. In study 1, bile acid output averaged 0.75+/-0.15 micromol/min in the CsA I group and 0.54+/-0.11 micromol/min in the OKT3 group on postoperative day 1. Bile flow and bile acid output then increased, and there was no significant difference between the two groups. The relative proportion of CDCA decreased to the same extent in both groups. In study 2, mean bile acid outputs on postoperative day 1 were 0.57+/-0.26 micromol/min and 0.55+/-0.15 micromol/min in the CsA 2 and FK506 groups, respectively. The following increase in bile acid secretion was significantly larger in the FK506 group. After transplantation, the relative proportion of CDCA decreased with time in both groups, but the reduction was more rapid in the FK506 group. In conclusion, CsA did not inhibit bile secretion during short-term treatment after liver transplantation. Compared with patients given CsA-based treatment, patients with FK506-based treatment recovered bile secretion more rapidly.


Asunto(s)
Bilis/efectos de los fármacos , Ciclosporina/efectos adversos , Inmunosupresores/efectos adversos , Trasplante de Hígado , Tacrolimus/efectos adversos , Adulto , Bilis/química , Bilis/metabolismo , Ácido Quenodesoxicólico/análisis , Ácido Cólico , Ácidos Cólicos/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Muromonab-CD3/efectos adversos , Estudios Prospectivos
4.
Transplantation ; 60(9): 933-8, 1995 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-7491696

RESUMEN

Familial amyloidotic polyneuropathy (FAP) is an inherited fatal form of amyloidosis caused by mutant transthyretin. The disease is characterized by progressive peripheral and autonomic neuropathy. Most of the transthyretin is produced by the liver, and we have shown previously that the metabolic deficiency can be corrected by liver transplantation. In the present study, the clinical results from the first 20 patients who underwent liver transplantation for FAP in Sweden are evaluated. Three of the patients suffered from renal failure and underwent a simultaneous kidney transplantation. Fourteen of the 20 patients (70%) are alive 10-52 months after transplantation. The patients' nutritional status at the time of transplantation had a significant impact on mortality and morbidity (P < 0.007). Long-standing disease was another negative prognostic factor (P < 0.02). One year after transplantation, the nutritional status had improved (P < 0.02). Improvements were also noted in walking capacity and for gastrointestinal and urogenital symptoms. The results show that liver transplantation offers an effective means to treat patients with FAP. The procedure should preferably be performed before the nutritional status is poor and advanced organ dysfunction has developed.


Asunto(s)
Neuropatías Amiloides/cirugía , Trasplante de Hígado , Adulto , Neuropatías Amiloides/genética , Neuropatías Amiloides/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Trasplante de Riñón , Trasplante de Hígado/mortalidad , Trasplante de Hígado/fisiología , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/epidemiología , Insuficiencia Renal/cirugía , Factores de Tiempo , Resultado del Tratamiento
5.
Transplantation ; 62(8): 1076-80, 1996 Oct 27.
Artículo en Inglés | MEDLINE | ID: mdl-8900305

RESUMEN

Ten allogeneic bone marrow transplant (BMT) recipients with hepatic venoocclusive disease (VOD) were treated with recombinant human tissue plasminogen activator (rt-PA). Two of them subsequently underwent orthotopic liver transplantation (OLT). One additional patient with VOD underwent OLT without prior rt-PA treatment. Treatment with rt-PA was started a median of 14 (1--35) days after BMT. The dose of rt-PA given to adults was 10-50 mg i.v. and that given to children was 3-10 mg i.v. Treatment was given for 2-4 days. In three patients, the dose was administered over a longer period or it was repeated. Four patients responded to rt-PA therapy and six did not. Eight patients suffered from hemorrhages, one intracranial and three gastrointestinal. Four patients required blood transfusions. Four had minor subcutaneous hemorrhages and/or epistaxis. One patient died of intracranial hemorrhage and five from hepatic and/or multiorgan failure. Two patients treated with rt-PA, 10 mg/day for 4 days, are alive; one is alive and well 3 months after BMT, the other has relapsed after 7 months. The three patients undergoing OLT died of chronic hepatic failure, cerebral edema, and pneumonia. Our experience suggests that rt-PA should not be administered in high doses and that the treatment should not be given over a longer period, because of the risk of severe hemorrhages.


Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Enfermedad Veno-Oclusiva Hepática/terapia , Trasplante de Hígado , Activador de Tejido Plasminógeno/uso terapéutico , Adulto , Bilirrubina/sangre , Femenino , Hemorragia/inducido químicamente , Enfermedad Veno-Oclusiva Hepática/etiología , Enfermedad Veno-Oclusiva Hepática/cirugía , Humanos , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/uso terapéutico , Análisis de Supervivencia , Terapia Trombolítica , Activador de Tejido Plasminógeno/efectos adversos , Ultrasonografía Doppler Dúplex
6.
Transplantation ; 69(10): 2043-8, 2000 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-10852594

RESUMEN

BACKGROUND: In histocompatibility mismatched experimental animals, a combination of T-cell-depleted autologous and allogeneic marrow may induce mixed chimerism and tolerance. Patients with large primary liver tumors have a poor outcome. We investigated whether it were possible to induce mixed chimerism and obtain an antitumor effect in a patient with a large primary liver cancer after combined liver and bone marrow transplantation (BMT). METHODS: A 46-year-old female with a primary non resectable liver cancer received a liver transplant from a cadaveric donor. Subsequently, she was conditioned with 4x2 Gy of total lymphoid irradiation, 120 mg/kg cyclophosphamide, and 7.5 Gy total body irradiation. Twelve days after liver transplantation, she received T-cell-depleted autologous:cadaveric 5/6 antigen HLA-mismatched marrow in a proportion of CD34+ cells of 0.5:3.0x10(6)/kg. Chimerism status was determined with polymerase chain reaction amplification of variable number tandem repeats from DNA obtained from CD3+, CD19+, and CD45+ magnetic-bead-separated cells. RESULTS: The early posttransplant period was uneventful; liver function was normal and the hematopoietic engraftment of donor and recipient origin was prompt. Alpha-fetoprotein levels dropped from 440 to 35 microg/l. One month after marrow transplantation, donor T-cells decreased markedly. Monoclonal antibody OKT-3 and 10(5)/kg donor T-cells were given. One month later, the patient developed diarrhea and abdominal pain. A colonoscopy showed moderate gastrointestinal acute graft-versus-host disease and a Cryptosporidium infection. Three months after BMT, she became a complete donor chimera. Chimera cells showed little, if any, reactivity in mixed lymphocyte cultures to recipient and donor cells, but reacted to third party. Five months after BMT, she developed progressive Aspergillus fumigatus pneumonia and died. No tumor was found at the autopsy. CONCLUSION: We obtained mixed donor-recipient hematopoietic chimerism without severe acute graft-versus-host-disease, after combined T-cell depleted autologous and allogeneic BMT and a transplantation of a liver from an HLA-mismatched cadaveric donor. Additional donor T-cells enhanced donor bone marrow engraftment, but rejected the autograft. On the basis of this first attempt, further clinical studies are warranted.


Asunto(s)
Trasplante de Médula Ósea , Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/terapia , Trasplante de Hígado/fisiología , Trasplante de Médula Ósea/inmunología , Cadáver , Carcinoma Hepatocelular/cirugía , Terapia Combinada , Femenino , Enfermedad Injerto contra Huésped , Humanos , Terapia de Inmunosupresión , Neoplasias Hepáticas/cirugía , Trasplante de Hígado/inmunología , Prueba de Cultivo Mixto de Linfocitos , Persona de Mediana Edad , Factores de Tiempo , Donantes de Tejidos , Recolección de Tejidos y Órganos/métodos , Quimera por Trasplante , Trasplante Autólogo , Trasplante Homólogo , Irradiación Corporal Total , alfa-Fetoproteínas/análisis
7.
Intern Med ; 33(11): 730-2, 1994 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7849393

RESUMEN

A 28-year-old male patient with familial amyloidotic polyneuropathy (FAP) underwent a liver transplantation from a heart-beating cadaveric donor in Sweden. He had suffered from the disease for 2.5 years. It took 5.5 hours to carry out the operation without blood transfusion. After the liver transplantation, serum amyloidgenic variant transthyretin (TTR) levels became extremely low and diarrhea stopped after the 7th day. On day 13, the patient was discharged from the hospital and one month after the transplantation, his general condition remained quite good. This is the first case of a Japanese patient with congenital metabolic disorders as well as FAP to receive a liver transplantation from a heart-beating cadaveric donor.


Asunto(s)
Neuropatías Amiloides/cirugía , Trasplante de Hígado , Adulto , Neuropatías Amiloides/sangre , Cadáver , Humanos , Japón , Masculino , Prealbúmina/análisis , Suecia , Donantes de Tejidos
8.
Lakartidningen ; 95(28-29): 3172-6, 1998 Jul 08.
Artículo en Sueco | MEDLINE | ID: mdl-9700261

RESUMEN

Recent advances, first and foremost the development of new immunosuppressive agents, have markedly improved the outcome of intestinal transplantation, which is a treatment option for patients with serious intestinal diseases who have become dependent on total parenteral nutrition. The first small bowel transplantation in Sweden was performed at Huddinge Hospital in 1997, in the adult patient with intestinal pseudo-obstruction. The article reports the course of this patient and an update of international progress in intestinal transplantation.


Asunto(s)
Obstrucción Intestinal/cirugía , Intestino Delgado/trasplante , Dolor Abdominal/cirugía , Adulto , Resultado Fatal , Femenino , Rechazo de Injerto , Historia del Siglo XX , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Inmunosupresores/sangre , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/patología , Obstrucción Intestinal/patología , Intestino Delgado/irrigación sanguínea , Intestino Delgado/patología , Persona de Mediana Edad , Complicaciones Posoperatorias/diagnóstico , Tacrolimus/administración & dosificación , Tacrolimus/efectos adversos , Tacrolimus/sangre
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda